Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcus Biosciences, Inc. on August 10, 2021. The report addresses a change in the composition of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Departure: Michael Quigley, Ph.D., resigned from the Board of Directors effective August 10, 2021, in connection with his departure from Gilead Sciences, Inc.
- Director Appointment: The Board appointed Linda Higgins, Senior Vice President of Research, External Innovation at Gilead, as a Class III director to fill the vacancy.
- Compensation: Dr. Higgins will not receive compensation for her service as a board member.
Outlook, Risks, and Management Commentary
The appointment of Dr. Higgins is pursuant to the Investor Rights Agreement dated May 27, 2020, between Arcus and Gilead. This agreement was entered into alongside an Option, License and Collaboration Agreement and a Common Stock Purchase Agreement. Arcus expects to enter into its standard form of indemnification agreement with Dr. Higgins. No specific risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Verify the terms of the Investor Rights Agreement with Gilead Sciences, Inc. regarding board seat appointments.
- Confirm the effective date of Dr. Quigley's resignation and Dr. Higgins' appointment.
- Review the standard indemnification agreement to be executed with the new director.